Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether combining the study drugs, lenvatinib and
pembrolizumab, is a safe and effective treatment for metastatic soft tissue sarcomas that
cannot be removed with surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Merck Sharp & Dohme Corp. Parker Institute for Cancer Immunotherapy